To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT02057250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants. Secondary Objective: To compare the pharmacokinetic (PK) exposure of sarilumab administered by AID versus prefilled syringes (PFS).
Study identification
- NCT ID
- NCT02057250
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 217 participants
Conditions and interventions
Conditions
Interventions
- Sarilumab Drug
- Auto-Injector Device (AID) Device
- Pre-filled Syringe (PFS) Device
- Methotrexate Drug
- Sulfasalazine Drug
- Leflunomide Drug
- Hydroxychloroquine Drug
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2014
- Primary completion
- Jan 31, 2015
- Completion
- Feb 29, 2016
- Last update posted
- Jun 19, 2017
2014 – 2016
United States locations
- U.S. sites
- 31
- U.S. states
- 16
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840152 | Huntsville | Alabama | 35801 | — |
| Investigational Site Number 840221 | Peoria | Arizona | 85381 | — |
| Investigational Site Number 840226 | Roseville | California | 95661 | — |
| Investigational Site Number 840223 | Boulder | Colorado | 80304 | — |
| Investigational Site Number 840229 | Miami | Florida | 33185 | — |
| Investigational Site Number 840236 | Orlando | Florida | 32804 | — |
| Investigational Site Number 840155 | Palm Harbor | Florida | 34684 | — |
| Investigational Site Number 840220 | South Miami | Florida | 33143 | — |
| Investigational Site Number 840202 | Hagerstown | Maryland | 21740 | — |
| Investigational Site Number 840232 | Flint | Michigan | 48504 | — |
| Investigational Site Number 840233 | Kalamazoo | Michigan | 49048 | — |
| Investigational Site Number 840037 | Tupelo | Mississippi | 38801 | — |
| Investigational Site Number 840112 | Lincoln | Nebraska | 68516 | — |
| Investigational Site Number 840039 | Albany | New York | 12208 | — |
| Investigational Site Number 840224 | Cincinnati | Ohio | 45219 | — |
| Investigational Site Number 840002 | Oklahoma City | Oklahoma | 73103 | — |
| Investigational Site Number 840065 | Tulsa | Oklahoma | 74135 | — |
| Investigational Site Number 840009 | Duncansville | Pennsylvania | 16635 | — |
| Investigational Site Number 840062 | Reading | Pennsylvania | 19611 | — |
| Investigational Site Number 840016 | North Charleston | South Carolina | 29406 | — |
| Investigational Site Number 840025 | Jackson | Tennessee | 38305 | — |
| Investigational Site Number 840038 | Austin | Texas | 78705 | — |
| Investigational Site Number 840230 | Carrollton | Texas | 75007 | — |
| Investigational Site Number 840001 | Dallas | Texas | 75231 | — |
| Investigational Site Number 840020 | Houston | Texas | 77034 | — |
| Investigational Site Number 840239 | Houston | Texas | 77034 | — |
| Investigational Site Number 840241 | Houston | Texas | 77034 | — |
| Investigational Site Number 840242 | Houston | Texas | 77034 | — |
| Investigational Site Number 840069 | Lubbock | Texas | 79424 | — |
| Investigational Site Number 840074 | Mesquite | Texas | 75150 | — |
| Investigational Site Number 840237 | Plano | Texas | 75042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02057250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2017 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02057250 live on ClinicalTrials.gov.